

|  |  |
| --- | --- |
| **Affiliation:** **Address:** **Contact:** |  |

**Narrative**

|  |
| --- |
| *Jill Bargonetti is a Full Professor at The City University of New York (CUNY) at Hunter College and The Graduate Center in the PhD Programs of Biology and Biochemistry. In 2015 she joined the Cornell Medical Center Hunter College Belfer Research team as an Adjunct Assistant Professor of Cell and Developmental Biology. Since arriving at CUNY in 1994 Dr. Bargonetti has received numerous awards and recognitions. In 1997 she received a National Science Foundation Career Award and also received the Presidential Early Career Award for Scientists and Engineers from President William Clinton. She was a member of the National Cancer Policy Board from 2002 until 2005 (a board of the Institution of Medicine and National Research Council of the National Academies) and currently serves as a standing member on the National Institutes of Health, Tumor Cell Biology study section until 2018. Professor Bargonetti is an expert in the fields of p53 and MDM2 biology. She has carried out extensive research on the function of wild-type p53 (which assists in the suppression of tumor cells), on oncogenic mutant p53 function (which is a tumor promoter), and on the p53-dependent and p53-independent functions of MDM2. Dr. Bargonetti has been recognized for her outreach and teaching accomplishments at the graduate and undergraduate levels. Classes she has designed include an undergraduate curriculum using p53-biology as an undergraduate biology exercise (used in Biology 302 since 1997 and now in Biology 303). She recently developed a choreographic movement based class called “Choreographing Genomics” (Biology 175) that uses Post-Modern dance choreographic concepts for students to explore genomics and the relationship of gene regulation to Cancer Biology. Dr. Bargonetti has graduated fourteen PhD recipients. In addition numerous undergraduate students have worked with Dr. Bargonetti on research projects and she has trained many undergraduates on p53 biology in the coordinated laboratory and lecture courses Molecular Genetics and Cell Biology.* |

**Other Positions**

|  |  |
| --- | --- |
|  |  |
| **Title** | *Adjunct Professor* |
| **Institution** | *Weill Cornell Medical College* |
| **Department** | *Cell Biology* |
| **Division** |  |
| **Title** | *Professor* |
| **Institution** | *CUNY Graduate Center* |
| **Department** | *Biology and Biochemistry* |
| **Division** |  |

**Awards and Honors**

|  |  |  |
| --- | --- | --- |
|  |  |  |
| **1997** |  | *From President William J. Clinton - Presidential Early Career Award for Scientists and Engineers* |
| **1998** |  | *CUNY Academy for the Humanities and Sciences - Felix Gross Endowment Award Citation: For Outstanding Scholarly Achievement* |
| **1998** |  | *New York Voice Award - New York Voice Award: in recognition of individuals who have made a significant improvement to the* |
| **2001** |  | *NYC Mayor Rudolph Gulliani - NYC Mayor’s Award, Young Investigator Category* |
| **2001** |  | *Association for Women in Science - Outstanding Woman Scientist Award* |
| **2005** |  | *New York University Graduate School of Arts and Sciences - Distinguished Alumni/ae Award* |
| **2005** |  | *SUNY Purchase - Presidential Distinguished Alumni/ae Award* |
| **2011** |  | *International Conference on Frontiers in Basic Cancer Research. - American Association for Cancer Research Minority-Serving Institution Faculty Scholar in Cancer Rese* |
| **2014** |  | *Harvard University - Jocelyn Spragg Invited Lecture: “Celebrating Diversity in the Biomedical Sciences”* |

**Publications**

|  |  |  |
| --- | --- | --- |
|  |  |  |
| **1.** | *Farooqi K, Ghazvini M, Pride LD, Mazzella L, White D, Pramanik A, Bargonetti J, Moore CW. A Protein in the Yeast Saccharomyces cerevisiae Presents DNA Binding Homology to the p53 Checkpoint Protein and Tumor Suppressor. Biomolecules. 2020 Mar 07; 10(3).* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32156076) |
| **2.** | *Xiao G, Lundine D, Annor GK, Canar J, Ellison V, Polotskaia A, Donabedian PL, Reiner T, Khramtsova GF, Olopade OI, Mazo A, Bargonetti J. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2020 Feb 01; 80(3):394-405.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31776133) |
| **3.** | *Gao C, Xiao G, Bargonetti J. Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis. Oncotarget. 2019 Aug 20; 10(49):5007-5010.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31489110) |
| **4.** | *Bargonetti J, Prives C. Gain-of-function mutant p53: history and speculation. J Mol Cell Biol. 2019 Jul 19; 11(7):605-609.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31283823) |
| **5.** | *Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O, Bargonetti J. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Res. 2019 01 14; 21(1):5.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30642351) |
| **6.** | *Loo LWM, Gao C, Shvetsov YB, Okoro DR, Hernandez BY, Bargonetti J. MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population. Breast Cancer Res Treat. 2019 Feb; 174(1):257-269.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30470976) |
| **7.** | *Kundu N, Brekman A, Kim JY, Xiao G, Gao C, Bargonetti J. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. Oncotarget. 2017 Jul 18; 8(29):47916-47930.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28615518) |
| **8.** | *Qiu WG, Polotskaia A, Xiao G, Di L, Zhao Y, Hu W, Philip J, Hendrickson RC, Bargonetti J. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. NPJ Breast Cancer. 2017; 3.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28232952) |
| **9.** | *Shtraizent N, Matsui H, Polotskaia A, Bargonetti J. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010022.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26703669) |
| **10.** | *Rosso M, Polotskaia A, Bargonetti J. Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. Oncotarget. 2015 Oct 27; 6(33):34573-91.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26416444) |
| **11.** | *Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 2015 Jun 15; 29(12):1298-315.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26080815) |
| **12.** | *Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC, Bargonetti J. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proc Natl Acad Sci U S A. 2015 Mar 17; 112(11):E1220-9.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25733866) |
| **13.** | *Xiao G, Kue P, Bhosle R, Bargonetti J. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. Cell Cycle. 2015; 14(5):744-54.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25565400) |
| **14.** | *Shi M, Shtraizent N, Polotskaia A, Bargonetti J, Matsui H. Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure. PLoS One. 2014; 9(6):e99351.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24937470) |
| **15.** | *Hoffman S, Martin D, Meléndez A, Bargonetti J. C. elegans CEP-1/p53 and BEC-1 are involved in DNA repair. PLoS One. 2014; 9(2):e88828.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24586407) |
| **16.** | *Rosso M, Okoro DE, Bargonetti J. Splice variants of MDM2 in oncogenesis. Subcell Biochem. 2014; 85:247-61.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25201199) |
| **17.** | *Okoro DR, Arva N, Gao C, Polotskaia A, Puente C, Rosso M, Bargonetti J. Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator. PLoS One. 2013; 8(10):e77643.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24147044) |
| **18.** | *Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C, Avantaggiati ML. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle. 2012 Dec 01; 11(23):4436-46.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23151455) |
| **19.** | *Polotskaia A, Hoffman S, Krett NL, Shanmugam M, Rosen ST, Bargonetti J. 8-Amino-adenosine activates p53-independent cell death of metastatic breast cancers. Mol Cancer Ther. 2012 Nov; 11(11):2495-504.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22973058) |
| **20.** | *Okoro DR, Rosso M, Bargonetti J. Splicing up mdm2 for cancer proteome diversity. Genes Cancer. 2012 Mar; 3(3-4):311-9.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23150764) |
| **21.** | *Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Børresen-Dale AL, Levine AJ, Bargonetti J, Prives C. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012 Jan 20; 148(1-2):244-58.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22265415) |
| **22.** | *Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res. 2011 Jan 11; 13(1):R3.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21223569) |
| **23.** | *Bargonetti J, Champeil E, Tomasz M. Differential toxicity of DNA adducts of mitomycin C. J Nucleic Acids. 2010 Jul 29; 2010.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20798760) |
| **24.** | *Boamah EK, Brekman A, Tomasz M, Myeku N, Figueiredo-Pereira M, Hunter S, Meyer J, Bhosle RC, Bargonetti J. DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1. Chem Res Toxicol. 2010 Jul 19; 23(7):1151-62.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20536192) |
| **25.** | *Paz MM, Ladwa S, Champeil E, Liu Y, Rockwell S, Boamah EK, Bargonetti J, Callahan J, Roach J, Tomasz M. Mapping DNA adducts of mitomycin C and decarbamoyl mitomycin C in cell lines using liquid chromatography/ electrospray tandem mass spectrometry. Chem Res Toxicol. 2008 Dec; 21(12):2370-8.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19053323) |
| **26.** | *Arva NC, Talbott KE, Okoro DR, Brekman A, Qiu WG, Bargonetti J. Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethn Dis. 2008; 18(2 Suppl 2):S2-1-8.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18646312) |
| **27.** | *Boamah EK, White DE, Talbott KE, Arva NC, Berman D, Tomasz M, Bargonetti J. Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways. ACS Chem Biol. 2007 Jun 15; 2(6):399-407.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17530733) |
| **28.** | *Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene. 2006 Nov 23; 25(55):7305-10.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16785993) |
| **29.** | *White DE, Talbott KE, Arva NC, Bargonetti J. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res. 2006 Apr 01; 66(7):3463-70.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16585169) |
| **30.** | *Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005 Jul 22; 280(29):26776-87.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15908423) |
| **31.** | *Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15550242) |
| **32.** | *Hui L, Abbas T, Pielak RM, Joseph T, Bargonetti J, Foster DA. Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol Cell Biol. 2004 Jul; 24(13):5677-86.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15199126) |
| **33.** | *Abbas T, White D, Hui L, Yoshida K, Foster DA, Bargonetti J. Inhibition of human p53 basal transcription by down-regulation of protein kinase Cdelta. J Biol Chem. 2004 Mar 12; 279(11):9970-7.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14699137) |
| **34.** | *Molina MP, Cain C, Bargonetti J. In vivo footprinting and DNA affinity chromatography for analysis of p53 DNA binding ability. Methods Mol Biol. 2003; 234:151-70.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12824531) |
| **35.** | *Abbas T, Olivier M, Lopez J, Houser S, Xiao G, Kumar GS, Tomasz M, Bargonetti J. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem. 2002 Oct 25; 277(43):40513-9.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12183457) |
| **36.** | *Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol. 2002 Jan; 14(1):86-91.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11790986) |
| **37.** | *Houser S, Koshlatyi S, Lu T, Gopen T, Bargonetti J. Camptothecin and Zeocin can increase p53 levels during all cell cycle stages. Biochem Biophys Res Commun. 2001 Dec 21; 289(5):998-1009.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11741290) |
| **38.** | *Chicas A, Molina P, Bargonetti J. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun. 2000 Dec 20; 279(2):383-90.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11118296) |
| **39.** | *Xiao G, Chicas A, Olivier M, Taya Y, Tyagi S, Kramer FR, Bargonetti J. A DNA damage signal is required for p53 to activate gadd45. Cancer Res. 2000 Mar 15; 60(6):1711-9.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10749144) |
| **40.** | *Boydston-White S, Gopen T, Houser S, Bargonetti J, Diem M. Infrared spectroscopy of human tissue. V. Infrared spectroscopic studies of myeloid leukemia (ML-1) cells at different phases of the cell cycle. Biospectroscopy. 1999; 5(4):219-27.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10478952) |
| **41.** | *Xiao G, White D, Bargonetti J. p53 binds to a constitutively nucleosome free region of the mdm2 gene. Oncogene. 1998 Mar 05; 16(9):1171-81.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9528859) |
| **42.** | *Bargonetti J, Chicas A, White D, Prives C. p53 represses Sp1 DNA binding and HIV-LTR directed transcription. Cell Mol Biol (Noisy-le-grand). 1997 Nov; 43(7):935-49.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9449526) |
| **43.** | *Chen X, Bargonetti J, Prives C. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res. 1995 Oct 01; 55(19):4257-63.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7671232) |
| **44.** | *Prives C, Bargonetti J, Farmer G, Ferrari E, Friedlander P, Wang Y, Jayaraman L, Pavletich N, Hubscher U. DNA-binding properties of the p53 tumor suppressor protein. Cold Spring Harb Symp Quant Biol. 1994; 59:207-13.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7587071) |
| **45.** | *Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 1993 Dec; 7(12B):2565-74.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8276239) |
| **46.** | *Bargonetti J, Wang PZ, Novick RP. Measurement of gene expression by translational coupling: effect of copy mutations on pT181 initiator synthesis. EMBO J. 1993 Sep; 12(9):3659-67.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8253088) |
| **47.** | *Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci U S A. 1993 Apr 15; 90(8):3319-23.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8475074) |
| **48.** | *Bargonetti J, Reynisdóttir I, Friedman PN, Prives C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 1992 Oct; 6(10):1886-98.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1398068) |
| **49.** | *Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature. 1992 Jul 02; 358(6381):83-6.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1614538) |
| **50.** | *Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 1992 Jul; 6(7):1143-52.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1628822) |
| **51.** | *Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell. 1991 Jun 14; 65(6):1083-91.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1646078) |
| **52.** | *Prives C, Bargonetti J, Friedman PN, Manfredi JJ, Wang EH. Functional consequences of the interactions of the p53 tumor suppressor protein and SV40 large tumor antigen. Cold Spring Harb Symp Quant Biol. 1991; 56:227-35.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1668081) |
| **53.** | *Noirot P, Bargonetti J, Novick RP. Initiation of rolling-circle replication in pT181 plasmid: initiator protein enhances cruciform extrusion at the origin. Proc Natl Acad Sci U S A. 1990 Nov; 87(21):8560-4.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2236066) |
| **54.** | *Iordanescu S, Bargonetti J. Staphylococcus aureus chromosomal mutations that decrease efficiency of Rep utilization in replication of pT181 and related plasmids. J Bacteriol. 1989 Aug; 171(8):4501-3.* | [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2753862) |

**THANK YOU FOR USING THE RTRN RESEARCH COLLABORATION AND PROFESSIONAL NETWORKING SERVICE.**